Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyCellularComponent	basement membrane	NID2 ACHE ACAN NPNT	9.46e-05	122	41	4	GO:0005604
Domain	SH3_2	MIA2 MYO15A ARHGAP33	7.64e-04	86	39	3	IPR011511
Domain	SH3_2	MIA2 MYO15A ARHGAP33	7.64e-04	86	39	3	PF07653
Domain	UIM	ANKIB1 HUWE1	1.14e-03	24	39	2	PS50330
Domain	UIM_dom	ANKIB1 HUWE1	1.24e-03	25	39	2	IPR003903
Domain	PX	PIK3C2A ARHGAP33	4.89e-03	50	39	2	PS50195
Domain	-	PIK3C2A ARHGAP33	5.08e-03	51	39	2	3.30.1520.10
Domain	Phox	PIK3C2A ARHGAP33	5.27e-03	52	39	2	IPR001683
Domain	-	GATA6 NR1D1	6.31e-03	57	39	2	3.30.50.10
Domain	Znf_NHR/GATA	GATA6 NR1D1	6.52e-03	58	39	2	IPR013088
Pubmed	Ultrastructural cartilage abnormalities in MIA/CD-RAP-deficient mice.	MIA2 ACAN CTAGE1	4.99e-07	13	43	3	11839810
Pubmed	Loss of leukemia inhibitory factor receptor beta or cardiotrophin-1 causes similar deficits in preganglionic sympathetic neurons and adrenal medulla.	TH CLCF1 ACHE	4.99e-07	13	43	3	16467531
Pubmed	The Role of Dot1l in Prenatal and Postnatal Murine Chondrocytes and Trabecular Bone.	DOT1L ACAN	1.49e-06	2	43	2	32083237
Pubmed	In vivo intra-articular contrast enhanced μCT imaging of mouse knee cartilage.	DOT1L ACAN	1.49e-06	2	43	2	36436817
Pubmed	A novel type of myosin encoded by the mouse deafness gene shaker-2.	LLGL1 MYO15A	1.49e-06	2	43	2	9703981
Pubmed	Increased susceptibility to develop spontaneous and post-traumatic osteoarthritis in Dot1l-deficient mice.	DOT1L ACAN	4.48e-06	3	43	2	30513362
Pubmed	Stimulation of L-type calcium channels increases tyrosine hydroxylase and dopamine in ventral midbrain cells induced from somatic cells.	CACNA1D TH	4.48e-06	3	43	2	32154672
Pubmed	Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells.	TH ACHE	8.94e-06	4	43	2	17050626
Pubmed	Mea6 controls VLDL transport through the coordinated regulation of COPII assembly.	MIA2 CTAGE1	8.94e-06	4	43	2	27311593
Pubmed	MEA6 Deficiency Impairs Cerebellar Development and Motor Performance by Tethering Protein Trafficking.	MIA2 CTAGE1	8.94e-06	4	43	2	31244610
Pubmed	Reduced cholesterol and triglycerides in mice with a mutation in Mia2, a liver protein that localizes to ER exit sites.	MIA2 CTAGE1	8.94e-06	4	43	2	21807889
Pubmed	Genetic and physical delineation of the region of the mouse deafness mutation shaker-2.	LLGL1 MYO15A	8.94e-06	4	43	2	9168970
Pubmed	E3 ligases Arf-bp1 and Pam mediate lithium-stimulated degradation of the circadian heme receptor Rev-erb alpha.	HUWE1 NR1D1	8.94e-06	4	43	2	20534529
Pubmed	Deletion of Mea6 in Cerebellar Granule Cells Impairs Synaptic Development and Motor Performance.	MIA2 CTAGE1	8.94e-06	4	43	2	33718348
Pubmed	Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes.	MIA2 CTAGE1	8.94e-06	4	43	2	12586826
Pubmed	STRAP regulates alternative splicing fidelity during lineage commitment of mouse embryonic stem cells.	GATA6 MIA2 CTAGE1	1.22e-05	36	43	3	33230114
Pubmed	cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing.	MIA2 CTAGE1	1.49e-05	5	43	2	12839582
Pubmed	Specific phosphopeptide enrichment with immobilized titanium ion affinity chromatography adsorbent for phosphoproteome analysis.	MIA2 CTAGE1	1.49e-05	5	43	2	18630941
Pubmed	Large scale localization of protein phosphorylation by use of electron capture dissociation mass spectrometry.	MIA2 CTAGE1	1.49e-05	5	43	2	19131326
Pubmed	Characterization and expression pattern of the novel MIA homolog TANGO.	MIA2 CTAGE1	1.49e-05	5	43	2	15183315
Pubmed	Mea6/cTAGE5 cooperates with TRAPPC12 to regulate PTN secretion and white matter development.	MIA2 CTAGE1	1.49e-05	5	43	2	38439956
Pubmed	A tissue-specific atlas of mouse protein phosphorylation and expression.	MIA2 CTAGE1	1.49e-05	5	43	2	21183079
Pubmed	Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes.	GATA6 POLR2A	3.12e-05	7	43	2	20081228
Pubmed	cTAGE5 deletion in pancreatic β cells impairs proinsulin trafficking and insulin biogenesis in mice.	MIA2 CTAGE1	3.12e-05	7	43	2	29133483
Pubmed	A Cancer-Specific Ubiquitin Ligase Drives mRNA Alternative Polyadenylation by Ubiquitinating the mRNA 3' End Processing Complex.	HUWE1 POLR2A	3.12e-05	7	43	2	31980388
Pubmed	Frizzled-3 is required for the development of major fiber tracts in the rostral CNS.	TH ACHE	3.12e-05	7	43	2	12351730
Pubmed	Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin.	DOT1L POLR2A	4.16e-05	8	43	2	21873227
Pubmed	Periphilin is strongly expressed in the murine nervous system and is indispensable for murine development.	TH ACHE	5.35e-05	9	43	2	19621438
Pubmed	Misexpression of MIA disrupts lung morphogenesis and causes neonatal death.	MIA2 CTAGE1	5.35e-05	9	43	2	18342301
Pubmed	Disorganized epithelial polarity and excess trophectoderm cell fate in preimplantation embryos lacking E-cadherin.	GATA6 LLGL1	6.68e-05	10	43	2	20826529
Pubmed	Reduced expression of neuropeptide genes in a genome-wide screen of a secretion-deficient mouse.	CACNA1D TH ACHE	7.98e-05	67	43	3	16987237
Pubmed	Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2.	GATA6 CTAGE1	8.15e-05	11	43	2	20694014
Pubmed	Orphan nuclear receptor Nurr1 is essential for Ret expression in midbrain dopamine neurons and in the brain stem.	TH ACHE	8.15e-05	11	43	2	11749040
Pubmed	Abnormal retinal development in the Btrc null mouse.	TH ACHE	8.15e-05	11	43	2	19705444
Pubmed	Inhibition of RIF1 by SCAI Allows BRCA1-Mediated Repair.	DOT1L POLR2A	9.78e-05	12	43	2	28700933
Pubmed	Expression of connexin30.2 in interneurons of the central nervous system in the mouse.	TH ACHE	9.78e-05	12	43	2	17942321
Pubmed	Neuronal Dot1l Activity Acts as a Mitochondrial Gene-Repressor Associated with Human Brain Aging via H3K79 Hypermethylation.	TH DOT1L	9.78e-05	12	43	2	36674903
Pubmed	A physical map of the mouse shaker-2 region contains many of the genes commonly deleted in Smith-Magenis syndrome (del17p11.2p11.2).	LLGL1 MYO15A	1.15e-04	13	43	2	10049592
Pubmed	Neonatal lethality of neural crest cell-specific Rest knockout mice is associated with gastrointestinal distension caused by aberrations of myenteric plexus.	TH ACHE	1.15e-04	13	43	2	25135772
Pubmed	Mks6 mutations reveal tissue- and cell type-specific roles for the cilia transition zone.	TH POLR2A	1.35e-04	14	43	2	30133325
Pubmed	cTAGE5/MEA6 plays a critical role in neuronal cellular components trafficking and brain development.	MIA2 CTAGE1	1.55e-04	15	43	2	30224460
Pubmed	A systems-wide screen identifies substrates of the SCFβTrCP ubiquitin ligase.	HUWE1 LLGL1 PIK3C2A BAG4	1.94e-04	232	43	4	25515538
Pubmed	Armc5 deletion causes developmental defects and compromises T-cell immune responses.	HUWE1 POLR2A	2.01e-04	17	43	2	28169274
Pubmed	Analysis of mice carrying targeted mutations of the glucocorticoid receptor gene argues against an essential role of glucocorticoid signalling for generating adrenal chromaffin cells.	TH ACHE	2.01e-04	17	43	2	10357937
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	GATA6 TH CDX4 NR1D1 ACHE MAML3	2.25e-04	709	43	6	22988430
Pubmed	Serological detection of cutaneous T-cell lymphoma-associated antigens.	MIA2 CTAGE1	2.26e-04	18	43	2	11149944
Pubmed	The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures.	DOT1L POLR2A	2.26e-04	18	43	2	21030982
Pubmed	FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals.	TH ACHE	2.26e-04	18	43	2	12682014
Pubmed	Adrenal Development in Mice Requires GATA4 and GATA6 Transcription Factors.	GATA6 TH	2.26e-04	18	43	2	25933105
Pubmed	Sox5 and Sox6 are required for notochord extracellular matrix sheath formation, notochord cell survival and development of the nucleus pulposus of intervertebral discs.	NID2 ACAN	2.26e-04	18	43	2	12571105
Pubmed	GATA6 is a regulator of sinus node development and heart rhythm.	GATA6 CACNA1D	2.80e-04	20	43	2	33443158
Pubmed	Regulation of the protocadherin Celsr3 gene and its role in globus pallidus development and connectivity.	TH ACHE	3.09e-04	21	43	2	25113559
Pubmed	Prediction of the coding sequences of unidentified human genes. XX. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.	DOT1L L3MBTL3 MAML3	3.19e-04	107	43	3	11347906
Pubmed	Ets1 is required for proper migration and differentiation of the cardiac neural crest.	GATA6 ACAN	3.40e-04	22	43	2	20356956
Pubmed	Essential role of the zinc finger transcription factor Casz1 for mammalian cardiac morphogenesis and development.	CACNA1D ACAN	3.72e-04	23	43	2	25190801
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	AKNA ORAI1 HUWE1 DOT1L PPRC1 POLR2A ARHGAP33	3.80e-04	1105	43	7	35748872
Pubmed	Genes in a refined Smith-Magenis syndrome critical deletion interval on chromosome 17p11.2 and the syntenic region of the mouse.	LLGL1 MYO15A	4.05e-04	24	43	2	11997338
Pubmed	Adamts18 modulates the development of the aortic arch and common carotid artery.	TH ACAN	4.76e-04	26	43	2	34189436
Pubmed	Conditional mutagenesis of Gata6 in SF1-positive cells causes gonadal-like differentiation in the adrenal cortex of mice.	GATA6 TH	5.14e-04	27	43	2	23471215
Pubmed	Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture.	DOT1L L3MBTL3 ACAN	5.52e-04	129	43	3	23563607
Pubmed	Eliminating SF-1 (NR5A1) sumoylation in vivo results in ectopic hedgehog signaling and disruption of endocrine development.	TH ACAN	5.53e-04	28	43	2	21820362
Pubmed	Basement membrane assembly of the integrin α8β1 ligand nephronectin requires Fraser syndrome-associated proteins.	NID2 NPNT	5.93e-04	29	43	2	22613833
Pubmed	Transcriptional corepressors HIPK1 and HIPK2 control angiogenesis via TGF-β-TAK1-dependent mechanism.	GATA6 PPRC1	5.93e-04	29	43	2	23565059
Pubmed	Comparative interactome analysis of α-arrestin families in human and Drosophila.	ANKIB1 HUWE1 LLGL1 POLR2A	6.02e-04	313	43	4	38270169
Pubmed	An atlas of combinatorial transcriptional regulation in mouse and man.	GATA6 POU2AF1 CDX4 L3MBTL3 MAML3 POLR2A	6.95e-04	877	43	6	20211142
Pubmed	The splicing regulator Rbfox2 is required for both cerebellar development and mature motor function.	CACNA1D HUWE1	7.69e-04	33	43	2	22357600
Pubmed	Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins.	NID2 RNPEP ACAN	7.91e-04	146	43	3	27068509
Pubmed	MEGF10 and MEGF11 mediate homotypic interactions required for mosaic spacing of retinal neurons.	SYNDIG1L TH	8.66e-04	35	43	2	22407321
Pubmed	Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation.	HUWE1 POLR2A	9.16e-04	36	43	2	35379950
Pubmed	Genetic determinants of height growth assessed longitudinally from infancy to adulthood in the northern Finland birth cohort 1966.	DOT1L ACAN	9.67e-04	37	43	2	19266077
Pubmed	The phagosomal proteome in interferon-gamma-activated macrophages.	MIA2 CTAGE1	1.13e-03	40	43	2	19144319
Pubmed	ARMC5 is part of an RPB1-specific ubiquitin ligase implicated in adrenal hyperplasia.	HUWE1 RNPEP POLR2A	1.15e-03	166	43	3	35687106
Interaction	CTAGE4 interactions	MIA2 CTAGE1	1.27e-05	3	42	2	int:CTAGE4
Interaction	CTAGE15 interactions	MIA2 CTAGE1	4.22e-05	5	42	2	int:CTAGE15
Interaction	CTAGE6 interactions	MIA2 CTAGE1	6.33e-05	6	42	2	int:CTAGE6
Interaction	CTAGE8 interactions	MIA2 CTAGE1	6.33e-05	6	42	2	int:CTAGE8
Interaction	BRINP1 interactions	DOT1L NR1D1 POLR2A	6.75e-05	38	42	3	int:BRINP1
GeneFamily	CTAGE family	MIA2 CTAGE1	2.23e-04	15	27	2	907
ToppCell	droplet-Kidney-KIDNEY-30m-Lymphocytic-Epcam____proximal_tube_epithelial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	POU2AF1 TMEM108 DOT1L PPRC1 POLR2A	3.84e-07	158	42	5	1d78578dc1f8ba43dacdccae1082c0b9d749f64d
ToppCell	facs-SCAT-Fat-3m-Lymphocytic-CD4-positive,_alpha-beta_T_cell\|SCAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	AKNA SYNDIG1L CLCF1 PRR7	1.37e-05	155	42	4	93513bab53b40e9c3c91ab8e3316ea00a4f66cd2
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1-6_VIP_PENK\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SYNDIG1L VGLL3 MIA2 NPNT	1.67e-05	163	42	4	551b3788bcf494c6121e64ce5af72266de12a06b
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	GATA6 TMEM108 ACAN NPNT	1.97e-05	170	42	4	a2c738e441ced90eeeb1fcc6ca3269b918aaa298
ToppCell	356C-Fibroblasts-Fibroblast-C_(Myofibroblast)-\|356C / Donor, Lineage, Cell class and subclass (all cells)	CACNA1D KIAA1210 NID2 TMEM108	2.31e-05	177	42	4	cdfd2f0ee2f692271b1525e414b0f645cdadb1f6
ToppCell	356C-Fibroblasts-Fibroblast-C_(Myofibroblast)\|356C / Donor, Lineage, Cell class and subclass (all cells)	CACNA1D KIAA1210 NID2 TMEM108	2.31e-05	177	42	4	db222faaecbe5600da39277243c4e7e764eb63c9
ToppCell	10x3'2.3-week_12-13-Mesenchymal_adipo\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	NID2 TMEM108 VGLL3 ACAN	2.86e-05	187	42	4	f1d0fc625e0e7881b3f290742fd7148d995eb71e
ToppCell	10x3'2.3-week_12-13-Mesenchymal_adipo-stroma\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	NID2 TMEM108 VGLL3 ACAN	2.86e-05	187	42	4	02e7246ef5ad41773d14426254e139b156d45c1d
ToppCell	10x3'2.3-week_12-13-Mesenchymal_adipo-stroma-adipo-CAR\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	NID2 TMEM108 VGLL3 ACAN	2.86e-05	187	42	4	08c73d125e0638c9e9878165bba2442c266c8a48
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CACNA1D TMEM108 VGLL3 NPNT	3.10e-05	191	42	4	6688cee34beee4f151ac17fccbc9c26a9aad72e1
ToppCell	COPD-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	CACNA1D TMEM108 MAML3 NPNT	3.17e-05	192	42	4	62904f94dfce430456f05066522cbf9bd29f4d7e
ToppCell	Control-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	CACNA1D TMEM108 MAML3 NPNT	3.23e-05	193	42	4	5896242f713ae5fd1a4ebb63827f15d7279dced2
ToppCell	COPD-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	GATA6 TMEM108 VGLL3 NPNT	3.50e-05	197	42	4	d51f484b4e01ac64233950d0b97fa88825ea1dbb
ToppCell	367C-Fibroblasts-Fibroblast-C_(Myofibroblast)\|367C / Donor, Lineage, Cell class and subclass (all cells)	CACNA1D TMEM108 VGLL3 NPNT	3.57e-05	198	42	4	a9afedbc0556faf4a46f7bf28f4a9adb3bc859d8
ToppCell	367C-Fibroblasts-Fibroblast-C_(Myofibroblast)-\|367C / Donor, Lineage, Cell class and subclass (all cells)	CACNA1D TMEM108 VGLL3 NPNT	3.57e-05	198	42	4	7b5350768f306ec528e271d2ac4470bf668ec6f0
ToppCell	Parenchymal-10x3prime_v2-Stromal-Fibroblastic-Fibro_alveolar\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	CACNA1D TMEM108 VGLL3 NPNT	3.72e-05	200	42	4	750ff51c9de08aecec230f4a402e0bf5a789f24c
ToppCell	Tracheal-10x3prime_v2-Stromal-Myofibroblastic-Muscle_perivascular_immune_recruiting\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	TMEM108 VGLL3 CLCF1 PPRC1	3.72e-05	200	42	4	410b1a31de21c57d87ca2104f61cf4a7d4dd2f30
Drug	bucumolol	PIK3C2A PPRC1	9.48e-06	3	41	2	CID000169786
Drug	ethylsarin	PIK3C2A ACHE	1.89e-05	4	41	2	CID000160541
Drug	fullerene C60	AKNA CACNA1D ORAI1 LLGL1 NR1D1 CLCF1 PPRC1 ACHE POLR2A ARHGAP33 LRRC15	4.85e-05	1498	41	11	ctd:C069837
Drug	corexit 9500	TH ACHE	6.61e-05	7	41	2	ctd:C470995
Drug	dimethyl phosphorodithioate	PIK3C2A ACHE	6.61e-05	7	41	2	CID000012959
Drug	ibotenic acid	TH RNPEP PPRC1 ACHE	6.82e-05	122	41	4	CID000001233
Drug	isopropyl methylphosphonic acid	PIK3C2A ACHE	8.80e-05	8	41	2	CID000015778
Drug	diisopropyl methylphosphonate	PIK3C2A ACHE	8.80e-05	8	41	2	CID000003073
Drug	p-chloroamphetamine	TH PPRC1 LRRC15	1.41e-04	56	41	3	CID000003127
Drug	procaine	CACNA1D ORAI1 PPRC1 ACHE	1.64e-04	153	41	4	CID000004914
Drug	cyanazine	TH ACHE	1.72e-04	11	41	2	ctd:C007168
Drug	DEMP	PIK3C2A ACHE	1.72e-04	11	41	2	CID000012685
Drug	Cycloheximide [66-81-9]; Up 200; 14.2uM; PC3; HT_HG-U133A	GATA6 DDX31 NR1D1 CLCF1	1.85e-04	158	41	4	5743_UP
Drug	8-Bromo Cyclic Adenosine Monophosphate	NID2 TH VGLL3 MIA2 NR1D1 L3MBTL3 CTAGE1	2.14e-04	693	41	7	ctd:D015124
Drug	2evc	ACHE ACAN	2.44e-04	13	41	2	CID000647499
Drug	NSC299933	ORAI1 ACHE	2.44e-04	13	41	2	CID000431902
Drug	Bim 22015	TH ACHE	2.44e-04	13	41	2	CID000132380
Drug	5-hydroxydopamine	TH ACHE	2.44e-04	13	41	2	CID000114772
Drug	NSC 208734	AKNA TH RNPEP	2.73e-04	70	41	3	CID000002008
Drug	ethylcholine mustard	RNPEP ACHE	2.84e-04	14	41	2	CID000199656
Drug	thiadiazolidinone	PPRC1 ACHE	2.84e-04	14	41	2	CID000443041
Drug	NSC7524	CACNA1D TH RNPEP ACHE	3.18e-04	182	41	4	CID000005657
Drug	protoberberine	TH ACHE	3.27e-04	15	41	2	CID000114943
Drug	Nicorette	CACNA1D POU2AF1 TH PIK3C2A PPRC1 ACHE	3.45e-04	529	41	6	CID000000942
Drug	3-isoreserpine	TH RNPEP PIK3C2A ACHE	3.74e-04	190	41	4	CID000005052
Drug	pentosan polysulfate	HUWE1 ACAN LRRC15	3.90e-04	79	41	3	CID000037720
Drug	MEK1/2 inhibitor	GATA6 PIK3C2A PPRC1 ACAN	3.97e-04	193	41	4	CID009549284
Drug	Clozapine [5786-21-0]; Up 200; 12.2uM; PC3; HT_HG-U133A	CACNA1D HUWE1 ACAN LRRC15	3.97e-04	193	41	4	4670_UP
Drug	ICI182,780; Down 200; 1uM; MCF7; HT_HG-U133A	CACNA1D TH HUWE1 BAG4	4.04e-04	194	41	4	7534_DN
Drug	5230742; Up 200; 17uM; MCF7; HT_HG-U133A_EA	CACNA1D LLGL1 MYO15A CLCF1	4.04e-04	194	41	4	862_UP
Drug	haloperidol; Down 200; 10uM; HL60; HT_HG-U133A	GATA6 NR1D1 CLCF1 PRR7	4.12e-04	195	41	4	2663_DN
Drug	H-7 dihydrochloride; Up 200; 100uM; PC3; HT_HG-U133A	NID2 TH ARHGAP33 PRR7	4.12e-04	195	41	4	5941_UP
Drug	Labetalol hydrochloride [32780-64-6]; Up 200; 11uM; PC3; HT_HG-U133A	VGLL3 HUWE1 ACAN CTAGE1	4.20e-04	196	41	4	4473_UP
Drug	Spironolactone [52-01-7]; Up 200; 9.6uM; PC3; HT_HG-U133A	HUWE1 ACAN POLR2A ARHGAP33	4.20e-04	196	41	4	5781_UP
Drug	Trioxsalen [3902-71-4]; Down 200; 17.6uM; HL60; HT_HG-U133A	DDX31 MIA2 RTL8C BAG4	4.20e-04	196	41	4	2516_DN
Drug	GW0072	PPRC1 ACHE	4.23e-04	17	41	2	CID000449532
Drug	Sulpiride [15676-16-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A	CACNA1D TH HUWE1 CLCF1	4.29e-04	197	41	4	1467_UP
Drug	Pirenperone [ 75444-65-4]; Up 200; 10.2uM; PC3; HT_HG-U133A	VGLL3 HUWE1 LLGL1 MIA2	4.29e-04	197	41	4	4679_UP
Drug	oxamic acid sodium salt; Up 200; 10000uM; MCF7; HG-U133A	NR1D1 CLCF1 ARHGAP33 PRR7	4.29e-04	197	41	4	439_UP
Drug	Prilocaine hydrochloride [1786-81-8]; Down 200; 15.6uM; PC3; HT_HG-U133A	VGLL3 HUWE1 NR1D1 LRRC15	4.29e-04	197	41	4	3727_DN
Drug	Lorglumide sodium salt [97964-56-2]; Up 200; 8.4uM; PC3; HT_HG-U133A	HUWE1 NR1D1 ACHE CTAGE1	4.29e-04	197	41	4	4658_UP
Drug	Dilazep dihydrochloride [20153-98-4]; Down 200; 6uM; HL60; HT_HG-U133A	MIA2 NR1D1 CLCF1 BAG4	4.37e-04	198	41	4	2333_DN
Drug	PHA-00851261E [724719-49-7]; Down 200; 10uM; MCF7; HT_HG-U133A	NR1D1 POLR2A ARHGAP33 BAG4	4.37e-04	198	41	4	3854_DN
Drug	Adenosine 5'-monophosphate monohydrate [18422-05-4]; Up 200; 11uM; MCF7; HT_HG-U133A	CACNA1D ACAN POLR2A BAG4	4.37e-04	198	41	4	3237_UP
Drug	Amoxapine [14028-44-5]; Up 200; 12.8uM; HL60; HG-U133A	CLCF1 MAML3 ACAN ARHGAP33	4.37e-04	198	41	4	2013_UP
Drug	Oxamniquine [21738-42-1]; Down 200; 14.4uM; PC3; HT_HG-U133A	NID2 VGLL3 PRR7 LRRC15	4.37e-04	198	41	4	4006_DN
Drug	Oxybutynin chloride [1508-65-2]; Up 200; 10.2uM; HL60; HG-U133A	DDX31 ACAN ARHGAP33 BAG4	4.37e-04	198	41	4	1551_UP
Drug	Pralidoxime chloride [51-15-0]; Up 200; 23.2uM; HL60; HT_HG-U133A	DDX31 NR1D1 ACAN CTAGE1	4.45e-04	199	41	4	3066_UP
Drug	nordihydroguaiaretic acid; Down 200; 1uM; HL60; HT_HG-U133A	GATA6 NR1D1 ARHGAP33 PRR7	4.45e-04	199	41	4	2683_DN
Drug	Methapyrilene hydrochloride [135-23-9]; Up 200; 13.4uM; MCF7; HT_HG-U133A	CACNA1D HUWE1 LLGL1 BAG4	4.45e-04	199	41	4	3205_UP
Drug	Acrylamide	TH NR1D1 ACHE ACAN	4.45e-04	199	41	4	ctd:D020106
Drug	Benzydamine hydrochloride [132-69-4]; Up 200; 11.6uM; MCF7; HT_HG-U133A	CACNA1D TH MYO15A ARHGAP33	4.45e-04	199	41	4	3169_UP
Drug	Oxalamine citrate salt [1949-20-8]; Down 200; 9.2uM; PC3; HT_HG-U133A	NID2 TH ACAN BAG4	4.45e-04	199	41	4	6624_DN
Drug	Hesperidin [520-26-3]; Up 200; 6.6uM; MCF7; HT_HG-U133A	MIA2 NR1D1 ACAN ARHGAP33	4.54e-04	200	41	4	2648_UP
Drug	Alfadolone acetate [23930-37-2]; Up 200; 10.2uM; HL60; HT_HG-U133A	NR1D1 CLCF1 ACAN CTAGE1	4.54e-04	200	41	4	3127_UP
Drug	thiocholine	TH ACHE	4.75e-04	18	41	2	CID000012234
Drug	Sulfamethoxazole	ACHE ACAN	4.75e-04	18	41	2	ctd:D013420
Drug	Chlorpromazine	TMEM108 NR1D1 CLCF1 L3MBTL3 ACHE BAG4	4.84e-04	564	41	6	ctd:D002746
Drug	N-methylcarbamate	ACHE LRRC15	5.31e-04	19	41	2	CID000030536
Drug	guanosine 3',5'-cyclic monophosphoric acid	CACNA1D TH DOT1L RNPEP ACHE POLR2A	5.46e-04	577	41	6	CID000000295
Drug	mecamylamine	TH RNPEP ACHE	5.53e-04	89	41	3	CID000004032
Drug	arotinolol	PIK3C2A PPRC1	5.89e-04	20	41	2	CID000002239
Drug	HI-6 chloride	PIK3C2A ACHE	5.89e-04	20	41	2	CID005484128
Drug	colchine	TH PIK3C2A CLCF1 ACHE ACAN	5.98e-04	383	41	5	CID000002833
Drug	vasopressin	TH RNPEP PIK3C2A CLCF1 PPRC1	6.34e-04	388	41	5	CID011979316
Drug	Soil Pollutants	TH ACHE	7.14e-04	22	41	2	ctd:D012989
Drug	3,5,6-trichloro-2-pyridinol	ACHE LRRC15	7.81e-04	23	41	2	CID000023017
Drug	azinphos-methyl	ACHE LRRC15	8.52e-04	24	41	2	CID000002268
Drug	isoamyl acetate	TH ACHE	9.25e-04	25	41	2	CID000031276
Drug	N-n-propylnorapomorphine	TH PPRC1	9.25e-04	25	41	2	CID000030137
Drug	N-methyl-DL-aspartic acid	CACNA1D ORAI1 TH RNPEP PIK3C2A ACHE	1.06e-03	655	41	6	CID000004376
Drug	guanethidine	TH RNPEP ACHE	1.11e-03	113	41	3	CID000003518
Drug	Lucifer yellow	TH RNPEP ACHE	1.11e-03	113	41	3	CID006335488
Drug	LMWH	NID2 TH PIK3C2A ACHE ACAN POLR2A	1.12e-03	663	41	6	CID000000772
Drug	Eprosartan-d3	PPRC1 OSCAR	1.16e-03	28	41	2	CID000060878
Drug	pentolinium	PPRC1 ACHE	1.16e-03	28	41	2	CID000005849
Drug	Tetracycline	TMEM108 RNPEP NR1D1 PIK3C2A L3MBTL3 POLR2A	1.17e-03	668	41	6	ctd:D013752
Drug	pirimiphos-methyl	RNPEP ACHE	1.25e-03	29	41	2	CID000034526
Drug	linalool	ACHE LRRC15	1.25e-03	29	41	2	CID000006549
Drug	dihydralazine	TH PPRC1	1.25e-03	29	41	2	CID000010230
Drug	Scopolamine Hydrobromide	CACNA1D NR1D1 ACHE	1.32e-03	120	41	3	ctd:D012601
Drug	carbofuran	ACHE LRRC15	1.33e-03	30	41	2	CID000002566
Drug	Lupex	TH RNPEP ACHE	1.45e-03	124	41	3	CID000042785
Drug	coelenteramide	PPRC1 ACHE	1.52e-03	32	41	2	CID005326781
Drug	Chitosan	TH ACAN	1.52e-03	32	41	2	ctd:D048271
Drug	trihexyphenidyl	TH ACHE	1.52e-03	32	41	2	CID000005572
Drug	2-aminoethyl diphenylborinate	CACNA1D ORAI1 RNPEP	1.55e-03	127	41	3	CID000001598
Drug	pimozide	CACNA1D ORAI1 TH	1.55e-03	127	41	3	CID000016362
Drug	AP-5	CACNA1D TH RNPEP	1.58e-03	128	41	3	CID000001216
Drug	temephos	ACHE BAG4	1.61e-03	33	41	2	CID000005392
Drug	aniracetam	NR1D1 PPRC1 PRR7	1.65e-03	130	41	3	CID000002196
Drug	polylactic acid-polyglycolic acid copolymer	TH ACAN	1.71e-03	34	41	2	ctd:C043435
Disease	docosahexaenoic acid measurement, sex interaction measurement	GATA6 CTAGE1	3.75e-05	7	40	2	EFO_0007761, EFO_0008343
Disease	FEV/FEC ratio	GATA6 CACNA1D NID2 MYO15A L3MBTL3 ACAN CTAGE1 NPNT	2.06e-04	1228	40	8	EFO_0004713
Disease	chronic obstructive pulmonary disease	CACNA1D LLGL1 DOT1L L3MBTL3 MAML3 NPNT	3.07e-04	688	40	6	EFO_0000341
Disease	portal hypertension (biomarker_via_orthology)	TH NR1D1	4.07e-04	22	40	2	DOID:10762 (biomarker_via_orthology)
Disease	gamma-linolenic acid measurement	DOT1L MAML3	4.85e-04	24	40	2	EFO_0007762
Disease	cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement	GATA6 LLGL1 L3MBTL3 CTAGE1	5.25e-04	276	40	4	EFO_0004612, EFO_0020943
Disease	brain cancer (implicated_via_orthology)	LLGL1 L3MBTL3	5.70e-04	26	40	2	DOID:1319 (implicated_via_orthology)
Disease	Developmental Academic Disorder	TH ACHE	7.11e-04	29	40	2	C1330966
Disease	Learning Disorders	TH ACHE	7.11e-04	29	40	2	C0023186
Disease	Learning Disturbance	TH ACHE	7.11e-04	29	40	2	C0751263
Disease	Adult Learning Disorders	TH ACHE	7.11e-04	29	40	2	C0751262
Disease	Learning Disabilities	TH ACHE	7.11e-04	29	40	2	C0751265
Disease	resting heart rate, chronic obstructive pulmonary disease	GATA6 CTAGE1	7.61e-04	30	40	2	EFO_0000341, EFO_0004351
Disease	lower urinary tract symptom, benign prostatic hyperplasia	GATA6 CTAGE1	8.66e-04	32	40	2	EFO_0000284, EFO_0008008
Disease	testosterone measurement	AKNA CACNA1D VGLL3 MYO15A L3MBTL3 ACHE POLR2A	1.48e-03	1275	40	7	EFO_0004908
Disease	multiple sclerosis (is_marker_for)	ACHE ACAN	2.02e-03	49	40	2	DOID:2377 (is_marker_for)
Disease	refractive error, age at onset, Myopia	CACNA1D L3MBTL3 POLR2A	2.28e-03	193	40	3	EFO_0004847, HP_0000545, MONDO_0004892
Disease	disease progression measurement	TMEM108 POLR2A	3.12e-03	61	40	2	EFO_0008336
Disease	lysophosphatidylcholine measurement	GATA6 CTAGE1	3.22e-03	62	40	2	EFO_0010224
Disease	heart rate	CACNA1D L3MBTL3 ACHE	3.51e-03	225	40	3	EFO_0004326
Disease	hearing loss	NID2 ACAN	3.75e-03	67	40	2	EFO_0004238
Disease	Parkinson's disease (is_marker_for)	TH ACHE	3.75e-03	67	40	2	DOID:14330 (is_marker_for)

Protein segments in the cluster

Peptide	Gene	Start	Entry
NVWTPYPRPTSPTPV	ACHE	131	P22303
PWPSSAPSAPPGNLY	BAG4	256	O95429
WPSLGVWGSPYSPPR	CDX4	66	O14627
PGWPPYLPDLSPGDS	RNPEP	486	Q9H4A4
SPYGPSPLGWPSSET	CTAGE1	486	Q96RT6
PPPSGYNAWDTLPSP	ANKIB1	291	Q9P2G1
SPVGAEPAVYPWPLP	DOT1L	11	Q8TEK3
TPGWPAVPAPYLAPL	LLGL1	376	Q15334
PPSSRPVFPPAYWTS	L3MBTL3	76	Q96JM7
SNWSPLGPPSSPYGA	MAML3	516	Q96JK9
GSTWWPPKTPYIPPI	NPNT	291	Q6UXI9
ASAFVYPWVPPPIPS	MYO15A	406	Q9UKN7
GAPPPPPSAVTYPDW	ORAI1	41	Q96D31
QWPPGLPGPSTYALP	PIK3C2A	141	O00443
VPPSPAPLGTSPYSW	DDX31	51	Q9H8H2
KGLSWQPPPYTPTPR	HUWE1	1111	Q7Z6Z7
PYTPSPPVPSWTELP	ACAN	841	P16112
TPSVPPASYHPKPWL	OSCAR	21	Q8IYS5
PPTHLSVPPRPWSYP	PRR7	126	Q8TB68
WGLISPSGTPLPPPY	PRSS41	186	Q7RTY9
RDSLAPSWETPPPYP	NID2	401	Q14112
PSWETPPPYPENGSI	NID2	406	Q14112
PTPATLQPLAPWTPY	POU2AF1	91	Q16633
APSSYPPTWPPGPAH	NR1D1	361	P20393
PPPPYPTPSWSLHSE	ARHGAP33	1266	O14559
PYSPYVGAPLTPAWP	GATA6	336	Q92908
GSSPRPPPGLWYLAT	AKNA	1316	Q7Z591
PVAPTPSKYTSPPWV	KIAA1210	1076	Q9ULL0
PSPSSQPAPPMYIWT	RTL8C	86	O15255
PSWPCYPHVSPSGYP	PPRC1	921	Q5VV67
VPWAPPPAPVSPYSS	PPRC1	961	Q5VV67
WATPPATPPYRDWTP	CACNA1D	1981	Q01668
PYGPSPLGWPSSETR	MIA2	1126	Q96PC5
GPYPYPETPPSWSCQ	SYNDIG1L	21	A6NDD5
VPSYPETPWYPDTPS	LRRC15	481	Q8TF66
YPLPQPLPGTEPTWT	CLCF1	156	Q9UBD9
PSPWPSGLASIPYEP	C11orf91	91	Q3C1V1
QTWFFPPPPAGSVSP	TEX44	231	Q53QW1
PWPPYFPSLSSPSGT	PRR19	261	A6NJB7
YSPAWSPTPGSPGSP	POLR2A	1561	P24928
HWLYPSPPLTPSFSP	PRR30	116	Q53SZ7
GPAPPPAVSESWPYP	VGLL3	196	A8MV65
PGSPAALPDSYPWPP	nan	131	Q8N6K4
LPTPAPGALWPQSPY	TPRX2	231	P0DV77
TPRTPLWGYSSSPQP	TMEM108	236	Q6UXF1
WPGTAAPAASYTPTP	TH	46	P07101